CompletedNCT00228059
52-week licarbazepine extension after a 3-week mania study
About this title
An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder.
Read the official source — NCT00228059This study evaluated the safety of Licarbazepine for people with bipolarity.
Medication studyAges 18–70United States
Understand this study
What did researchers investigate?
This study evaluated the safety of Licarbazepine for people with bipolarity.
Who was this study for?
Listed age limits: 18 years to 70 years.
- Listed locations
- CerritosSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateJanuary 2005
- Recruitment status
- Completed
- Enrollment listed in the registry
- 132
- Sponsor
- Novartis
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 70 Years
- Official registry ID
- NCT00228059
- Official title
Show the full official title
A 52-week, Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine 750- 2000 mg/Day in the Treatment of Manic Episodes of Bipolar I Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Cerritos
Questions about this study
What did researchers investigate?
This study evaluated the safety of Licarbazepine for people with bipolarity.
Who is behind this study?
The study sponsor is Novartis.
Did this study involve medication?
Yes. The study involved medication, including Licarbazepine.
Who was this study for?
Listed age limits: 18 years to 70 years.
